ProKidney Corp. (PROK) - Net Assets
Based on the latest financial reports, ProKidney Corp. (PROK) has net assets worth $300.79 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($335.57 Million) and total liabilities ($34.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of ProKidney Corp. to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $300.79 Million |
| % of Total Assets | 89.64% |
| Annual Growth Rate | 63.25% |
| 5-Year Change | 1017.48% |
| 10-Year Change | N/A |
| Growth Volatility | 659.05 |
ProKidney Corp. - Net Assets Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s net assets have evolved over time, based on quarterly financial data. See PROK cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ProKidney Corp. (2019–2025)
The table below shows the annual net assets of ProKidney Corp. from 2019 to 2025. For live valuation and market cap data, see how much is ProKidney Corp. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $300.79 Million | -25.11% |
| 2024-12-31 | $401.64 Million | +2.63% |
| 2023-12-31 | $391.34 Million | -22.50% |
| 2022-12-31 | $504.94 Million | +1775.91% |
| 2021-12-31 | $26.92 Million | +172.88% |
| 2020-12-31 | $9.86 Million | -37.90% |
| 2019-12-31 | $15.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ProKidney Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 119022000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $30.00K | % |
| Other Comprehensive Income | $56.00K | % |
| Other Components | $258.55 Million | % |
| Total Equity | $-1.01 Billion | 100.00% |
ProKidney Corp. Competitors by Market Cap
The table below lists competitors of ProKidney Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
King Core Electronics Inc
TW:6155
|
$248.48 Million |
|
Orrön Energy AB (publ)
ST:ORRON
|
$248.61 Million |
|
Magnora ASA
OL:MGN
|
$248.61 Million |
|
Rane Holdings Limited
NSE:RANEHOLDIN
|
$248.69 Million |
|
Springsnow Food Group Co Ltd
SHG:605567
|
$248.47 Million |
|
The Korea Fund Inc
F:KOF1
|
$248.44 Million |
|
Qinhuangdao Port Co Ltd
F:QHD
|
$248.37 Million |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
$248.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ProKidney Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -994,954,000 to -1,011,197,000, a change of -16,243,000.
- Net loss of 68,986,000 reduced equity.
- New share issuances of 24,247,000 increased equity.
- Other comprehensive income decreased equity by 74,000.
- Other factors increased equity by 28,570,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.99 Million | -6.82% |
| Share Issuances | $24.25 Million | +2.4% |
| Other Comprehensive Income | $-74.00K | -0.01% |
| Other Changes | $28.57 Million | +2.83% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares ProKidney Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.20 | $1.75 | x |
| 2020-12-31 | $0.05 | $1.75 | x |
| 2021-12-31 | $0.84 | $1.75 | x |
| 2022-12-31 | $-17.82 | $1.75 | x |
| 2023-12-31 | $-17.88 | $1.75 | x |
| 2024-12-31 | $-10.16 | $1.75 | x |
| 2025-12-31 | $-7.55 | $1.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ProKidney Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7725.20%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-139.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -501.26% | 0.00% | 0.00x | 1.23x | $-81.20 Million |
| 2020 | -271.18% | 0.00% | 0.00x | 1.69x | $-27.74 Million |
| 2021 | -204.87% | 0.00% | 0.00x | 1.50x | $-57.84 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $1.63 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $74.87 Million |
| 2024 | 0.00% | -80507.89% | 0.00x | 0.00x | $38.31 Million |
| 2025 | 0.00% | -7725.20% | 0.00x | 0.00x | $32.13 Million |
Industry Comparison
This section compares ProKidney Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ProKidney Corp. (PROK) | $300.79 Million | -501.26% | 0.12x | $248.48 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more